| Recruiting | Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma NCT07042438 | City of Hope Medical Center | Phase 2 |
| Recruiting | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minoritie NCT06859008 | City of Hope Medical Center | Phase 1 |
| Recruiting | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lym NCT07098364 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL NCT07393204 | Andrés José Maria Ferreri | — |
| Recruiting | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto NCT06649812 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726 | University of Washington | Phase 2 |
| Recruiting | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chime NCT06854159 | Joseph Tuscano | Phase 2 |
| Recruiting | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for NCT06905509 | Joseph Tuscano | Phase 2 |
| Recruiting | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049 | Yazeed Sawalha | Phase 1 / Phase 2 |
| Recruiting | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527 | AIDS Malignancy Consortium | Phase 1 |
| Terminated | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Epcoritamab-CAR T Cells for Large B-cell Lymphomas NCT06458439 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Recruiting | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymp NCT05672251 | City of Hope Medical Center | Phase 2 |
| Recruiting | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment NCT05890352 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma NCT06047197 | Beijing Yongtai Ruike Biotechnology Company Ltd | Phase 1 |
| Recruiting | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies NCT05453396 | University of Washington | Phase 2 |
| Recruiting | Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractor NCT05800405 | City of Hope Medical Center | EARLY_Phase 1 |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 | BeOne Medicines | Phase 1 |
| Recruiting | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lym NCT05633615 | SWOG Cancer Research Network | Phase 2 |
| Withdrawn | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Rec NCT05228249 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymph NCT05359211 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination NCT05267054 | BeiGene | Phase 1 / Phase 2 |
| Completed | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Larg NCT04890236 | Emory University | EARLY_Phase 1 |
| Recruiting | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for t NCT05052528 | Mehrdad Abedi, MD | Phase 1 |
| Active Not Recruiting | Copanlisib Plus Venetoclax in R/R DLBCL NCT04572763 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibi NCT05068440 | BeiGene | Phase 2 |
| Completed | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy NCT05075603 | NeoImmuneTech | Phase 1 |
| Withdrawn | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL NCT04995536 | City of Hope Medical Center | Phase 1 |
| Recruiting | DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relap NCT04920617 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 2 |
| Not Yet Recruiting | A Phase I/II Study of Diffuse Large B-cell Lymphoma NCT04856137 | National Health Research Institutes, Taiwan | Phase 1 / Phase 2 |
| Active Not Recruiting | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in S NCT04833114 | GWT-TUD GmbH | Phase 3 |
| Active Not Recruiting | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy NCT04665765 | City of Hope Medical Center | Phase 2 |
| Unknown | Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL NCT04659434 | Qian Wenbin | Phase 2 |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Active Not Recruiting | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapse NCT04384484 | ADC Therapeutics S.A. | Phase 3 |
| Completed | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma NCT04432506 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Withdrawn | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphom NCT04285268 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy NCT04409314 | University of California, San Francisco | — |
| Unknown | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Wit NCT04870853 | M.D. Anderson Cancer Center | — |
| Terminated | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymph NCT04156828 | University of Washington | Phase 1 |
| Terminated | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients Wit NCT04205838 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Unknown | Secondary Prognostic Index in RefrActory Lymphoma NCT04804865 | Weprom | — |
| Completed | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell NCT03484819 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma NCT03892044 | David Bond, MD | Phase 1 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transp NCT03579927 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem NCT03259503 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma NCT03688152 | Incyte Corporation | Phase 1 |
| Completed | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma NCT03309878 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Dr NCT03321643 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participa NCT03583424 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Tr NCT03488251 | Molecular Templates, Inc. | Phase 2 |
| Terminated | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Cente NCT03558750 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL NCT03305445 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Terminated | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitabl NCT03422523 | University Hospital Southampton NHS Foundation Trust | Phase 2 |
| Completed | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or NCT03440567 | City of Hope Medical Center | Phase 1 |
| Recruiting | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomo NCT03418038 | Mayo Clinic | Phase 2 |
| Terminated | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymph NCT03401853 | University of Washington | Phase 2 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patient NCT03019640 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymp NCT03136497 | Hackensack Meridian Health | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. NCT03150329 | City of Hope Medical Center | Phase 1 |
| Completed | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) NCT02658968 | Nordic Nanovector | Phase 1 |
| Active Not Recruiting | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin NCT02992522 | Beth Christian | Phase 1 |
| Active Not Recruiting | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896 | David Bond, MD | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220 | Kami Maddocks | Phase 1 |
| Completed | A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects NCT02976857 | Shanghai AbelZeta Ltd. | Phase 1 |
| Completed | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02706405 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT02874404 | University of Nebraska | Phase 2 |
| Completed | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Lar NCT02926833 | Kite, A Gilead Company | Phase 1 / Phase 2 |
| Active Not Recruiting | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphom NCT02628405 | Academic and Community Cancer Research United | Phase 1 / Phase 2 |
| Terminated | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL NCT02572453 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With R NCT02405078 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Terminated | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL NCT02366663 | City of Hope Medical Center | Phase 3 |
| Completed | Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell L NCT02219737 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin NCT02051257 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractor NCT01959698 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse L NCT02077166 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01955499 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Rel NCT01434472 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell NCT01431209 | University of Nebraska | Phase 2 |